Differential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy-Reference-Cited by-同舟云学术

Differential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy

Published:2023-03-13 Issue: Volume:Publish Ahead of Print Page:
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:

Author:

Li Yongyin,Wen Chunhua,Gu Shuqin,Wang Weibin,Guo Ling,Li Chris Kafai,Yi Xuan,Zhou Yang,Dong Zheyu,Fu Xin,Zhong Shihong,Wang Yuhao,Huang Kuiyuan,Yin Junhua,Zhong Chunxiu,Liang Xieer,Fan Rong,Chen Haitao,Jiang Deke,Zhang Xiaoyong,Sun Jian,Tang Libo,Peng Jie,Hou Jinlin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Reference32 articles.

1. Therapeutic strategies for hepatitis B virus infection: towards a cure;Fanning;Nat Rev Drug Discov,2019

2. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management;Chang;J Hepatol,2014

3. HBsAg seroclearance with NUCs: rare but important;Cornberg;Gut,2014

4. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation;Rivino;J Clin Invest,2018

5. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients;García-López;J Hepatol,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg‐negative hepatitis B virus‐related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis;Cancer Medicine;2024-08

2. Priming and Maintenance of Adaptive Immunity in the Liver;Annual Review of Immunology;2024-06-28

3. Clinical implications of hepatitis B virus core antigen‐mediated immunopathologic T cell responses in chronic hepatitis B;Journal of Medical Virology;2024-03

4. mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model;Vaccines;2024-02-25

5. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B;Hepatology Communications;2023-12